When it comes to personalized medicine, speed can make all the difference in the world for patients. That’s what makes today’s announcement that Intel Corporation and the Broad Institute have dramatically improved the time it takes to analyze genetic information and detect genetic variants associated with medical conditions so exciting.

 

By optimizing the latest version of the Broad’s Genome Analysis Toolkit (GATK) 3.1 for Intel® Advanced Vector Extensions (Intel® AVX) in Intel® Xeon servers, Intel and the Broad were able to achieve three to five times overall improvement in variant discovery to meet the challenges of research, and accelerate discovery.

 

These improvements enable a whole genome to now be processed in one day instead of three. Imagine that you were a patient waiting for results. Cutting wait times by two-thirds is a huge step in the right direction for improving care and outcomes using technology.

 

Together with new methods, GATK 3.1 can now analyze datasets consisting of tens of thousands of DNA samples, 100 times what was previously achievable. The improved speed for variant analysis in large association studies will help enable new medical discoveries for conditions such as cancer, neurodegenerative disorders, and cardiovascular disease that were never before possible.

 

What’s the bottom line? Intel and the Broad are improving the quality and performance of the whole GATK pipeline in order to benefit patients worldwide. The computational bottlenecks that stand in the way of scientific discovery are being solved, and that will make personalized medicine a reality for everyone.

 

Read more from the Broad about its take on today’s announcement.

 

What questions do you have about GATK or personalized medicine?

 

Learn more about GATK 3.1 for academic, noncommercial use or for commercial uses.